Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAY-2402234 是一种选择性二氢乳清酸脱氢酶的抑制剂,可研究骨髓恶性肿瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,480 | 现货 | ||
2 mg | ¥ 2,230 | 现货 | ||
5 mg | ¥ 3,690 | 现货 | ||
10 mg | ¥ 5,290 | 现货 | ||
25 mg | ¥ 8,230 | 现货 | ||
50 mg | ¥ 10,900 | 现货 | ||
100 mg | ¥ 14,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 4,220 | 现货 |
产品描述 | BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH) for the treatment of myeloid malignancies.BAY 2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity. |
体外活性 | BAY-2402234 induces differentiation of AML cell lines also in a sub-nanomolar to low-nanomolar range which demonstrates the anticipated mode of action in cellular mechanistic assays[1]. BAY-2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity. It potently inhibits proliferation of AML cell lines in the sub-nanomolar to low-nanomolar range in vitro. |
体内活性 | BAY-2402234 exhibits strong in vivo anti-tumor efficacy in monotherapy in several subcutaneous and disseminated AML xenografts and AML patient-derived xenograft (PDX) models. BAY-2402234 induces AML differentiation in vivo as detected by upregulation of differentiation cell surface markers in xenograft and PDX models after treatment with the inhibitor. Target engagement of the novel DHODH inhibitor BAY-2402234 can be observed by increase of tumoral and plasma dihydroorotate levels after treatment with the inhibitor. Moreover, differentiation-associated transcriptomic changes are evident following a single administration of BAY-2402234 in vivo[1]. |
分子量 | 520.84 |
分子式 | C21H18ClF5N4O4 |
CAS No. | 2225819-06-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 124 mg/mL(238.08 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.92 mL | 9.5999 mL | 19.1998 mL | 47.9994 mL |
5 mM | 0.384 mL | 1.92 mL | 3.84 mL | 9.5999 mL | |
10 mM | 0.192 mL | 0.96 mL | 1.92 mL | 4.7999 mL | |
20 mM | 0.096 mL | 0.48 mL | 0.96 mL | 2.4 mL | |
50 mM | 0.0384 mL | 0.192 mL | 0.384 mL | 0.96 mL | |
100 mM | 0.0192 mL | 0.096 mL | 0.192 mL | 0.48 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BAY-2402234 2225819-06-5 Cell Cycle/Checkpoint DNA Damage/DNA Repair Metabolism Dehydrogenase DNA/RNA Synthesis inhibit Inhibitor DHODH BAY 2402234 BAY2402234 Dihydroorotate Dehydrogenase inhibitor